Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients : Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Autor: Averbuch, Diana, Tridello, Gloria, Hoek, Jennifer, Mikulska, Malgorzata, Akan, Hamdi, San Segundo, Lucrecia Yaňez, Pabst, Thomas, Özçelik, Tülay, Klyasova, Galina, Donnini, Irene, Wu, Depei, Gülbas, Zafer, Zuckerman, Tsila, de Sousa, Aida Botelho, Beguin, Yves, Xhaard, Aliénor, Bachy, Emmanuel, Ljungman, Per, de la Camara, Rafael, Rascon, Jelena, Camps, Isabel Ruiz, Vitek, Antonin, Patriarca, Francesca, Cudillo, Laura, Vrhovac, Radovan, Shaw, Peter J., Wolfs, Tom, O’Brien, Tracey, Avni, Batia, Silling, Gerda, Sabty, Firas Al, Graphakos, Stelios, Sankelo, Marja, Sengeloev, Henrik, Pillai, Srinivas, Matthes, Susanne, Melanthiou, Frederiki, Iacobelli, Simona, Styczynski, Jan, Engelhard, Dan, Cesaro, Simone

Publikováno v: Clinical Infectious Diseases, 2017 Dec 01. 65(11), 1819-1828.

Externí odkaz: https://www.jstor.org/stable/26524722

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group

Autor: Kolonen, Aarne, Sinisalo, Marjatta, Huhtala, Heini, Rimpiläinen, Johanna, Rintala, Hannele, Sankelo, Marja, Koivunen, Elli, Silvennoinen, Raija, Räty, Riikka, Ruutu, Tapani, Volin, Liisa, Porkka, Kimmo, Jantunen, Esa, Nousiainen, Tapio, Kuittinen, Taru, Penttilä, Karri, Pyörälä, Marja, Säily, Marjaana, Koistinen, Pirjo, Kauppila, Marjut, Itälä-Remes, Maija, Ollikainen, Hanna, Rauhala, Auvo, Kairisto, Veli, Pelliniemi, Tarja Terttu, Elonen, Erkki

Publikováno v: European journal of haematologyREFERENCES. 109(3)

Objectives: AML-2003 study sought to compare the long-term efficacy and safety of IAT and IdAraC-Ida in induction chemotherapy of acute myeloid leukemia (AML) and introduce the results of an integrated genetic and clinical risk classification guided

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3ff4b8a80fc48d09a8011c986d379909
https://pubmed.ncbi.nlm.nih.gov/35634931

Impact of the number of cryopreserved CD34⁺ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Autor: Partanen, Anu, Turunen, Antti, Silvennoinen, Raija, Valtola, Jaakko, Pyörälä, Marja, Siitonen, Timo, Sikiö, Anu, Putkonen, Mervi, Sankelo, Marja, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, Varmavuo, Ville

Publikováno v: Journal of Clinical Apheresis; Feb2023, Vol. 38 Issue 1, p33-44, 12p

Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Autor: Silvennoinen, Raija Helena, Nahi, Hareth, Anttila , Pekka, Koskenvesa, Perttu, Lievonen, Juha, Marttila, Anu, Varmavuo, Ville, Sikiö, Anu, Nurmi, Marita, Säily, Marjaana, Partanen, Anu, Sankelo, Marja, Luoma, Sini, Mäntymaa, Pentti, Ilveskero, Sorella, Eshoj, Henrik, Kongsgaard Nielsen, Lene, Jantunen, Esa, Heckman, Caroline

Publikováno v: Silvennoinen, R H, Nahi, H, Anttila, P, Koskenvesa, P, Lievonen, J, Marttila, A, Varmavuo, V, Sikiö, A, Nurmi, M, Säily, M, Partanen, A, Sankelo, M, Luoma, S, Mäntymaa, P, Ilveskero, S, Eshoj, H R, Nielsen, L K, Jantunen, E & Heckman, C 2020, ' Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients ', Blood, bind 136, nr. Supplement 1, 20 . https://doi.org/10.1182/blood-2020-138447
Silvennoinen, R H, Nahi, H, Anttila, P, Koskenvesa, P, Lievonen, J, Marttila, A, Varmavuo, V, Sikiö, A, Nurmi, M, Säily, M, Partanen, A, Sankelo, M, Luoma, S, Mäntymaa, P, Ilveskero, S, Eshoj, H, Kongsgaard Nielsen, L, Ilveskero, S, Jantunen, E & Heckman, C 2020, ' Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients ', Blood, vol. 136, no. Suppl. 1, 20 . https://doi.org/10.1182/blood-2020-138447

Introduction: Due to its heterogenous nature including evolving mutations, multiple myeloma (MM) is still an incurable disease. Several novel agents have been introduced during the last decade resulting in prolonged median overall survival (OS) up to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be1bc46f1a34eca20ae61ed5e81f3fc
https://pure.au.dk/portal/da/publications/carfilzomib-elotuzumab-and-dexamethasone-for-relapsed-or-refractory-myeloma-patients(3240504a-3c7b-419a-93ca-f86c08a7f71b).html